Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma

被引:160
作者
Ruan, Shaobo [1 ]
He, Qin [1 ]
Gao, Huile [1 ]
机构
[1] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
DUAL TARGETING DELIVERY; DRUG-DELIVERY; CANCER NANOTECHNOLOGY; DOXORUBICIN DELIVERY; PEPTIDE; MICELLES; SYSTEMS; CELLS; BIODISTRIBUTION; EXPRESSION;
D O I
10.1039/c5nr01408e
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To improve glioma targeting delivery efficiency and to monitor drug delivery and treatment outcome, a novel tumor microenvironment sensitive size-shrinkable theranostic system was constructed and evaluated. The G-AuNPs-DC-RRGD system was constructed by fabricating small sized gold nanoparticles (AuNPs) onto matrix metalloproteinase-2 (MMP-2) degradable gelatin nanoparticles (GNPs), doxorubicin (DOX) and Cy5.5 were decorated onto AuNPs through a hydrazone bond to enable the system with pH triggered cargoes release, and RRGD, a tandem peptide of RGD and octarginine was surface-modified onto the system to enable it with glioma active targeting ability. In vitro, the size of G-AuNPs-DC-RRGD could effectively shrink from 188.2 nm to 55.9 nm after incubation with MMP-2, while DOX and Cy5.5 were released in a pH dependent manner. Cellular uptake demonstrated that G-AuNPs-DC-RRGD could be effectively taken up by cells with higher intensity than G-AuNPs-DC-PEG. A study of tumor spheroids further demonstrated that the particles with smaller size showed better penetration ability, while RRGD modification could further improve permeability. In vivo, G-AuNPs-DC-RRGD displayed the best glioma targeting and accumulation efficiency, with good colocalization with neovessels. Cy5.5 also was colocalized well with DOX, indicating that Cy5.5 could be used for imaging of DOX delivery.
引用
收藏
页码:9487 / 9496
页数:10
相关论文
共 43 条
[1]   RETRACTED: Down-regulation of integrin αvβ3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes (Retracted article. See vol. 295, pg. 13134, 2020) [J].
Adachi, Y ;
Lakka, SS ;
Chandrasekar, N ;
Yanamandra, N ;
Gondi, CS ;
Mohanam, S ;
Dinh, DH ;
Olivero, WC ;
Gujrati, M ;
Tamiya, T ;
Ohmoto, T ;
Kouraklis, G ;
Aggarwal, B ;
Rao, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) :47171-47177
[2]   Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy [J].
Ansari, Celina ;
Tikhomirov, Grigory A. ;
Hong, Su Hyun ;
Falconer, Robert A. ;
Loadman, Paul M. ;
Gill, Jason H. ;
Castaneda, Rosalinda ;
Hazard, Florette K. ;
Tong, Ling ;
Lenkov, Olga D. ;
Felsher, Dean W. ;
Rao, Jianghong ;
Daldrup-Link, Heike E. .
SMALL, 2014, 10 (03) :566-575
[3]   Targeted drug delivery to tumors: Myths, reality and possibility [J].
Bae, You Han ;
Park, Kinam .
JOURNAL OF CONTROLLED RELEASE, 2011, 153 (03) :198-205
[4]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[5]   αvβ3 and αvβ5 integrin expression in glioma periphery [J].
Bello, L ;
Francolini, M ;
Marthyn, P ;
Zhang, JP ;
Carroll, RS ;
Nikas, DC ;
Strasser, JF ;
Villani, R ;
Cheresh, DA ;
Black, PM .
NEUROSURGERY, 2001, 49 (02) :380-389
[6]   Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology [J].
Bertrand, Nicolas ;
Wu, Jun ;
Xu, Xiaoyang ;
Kamaly, Nazila ;
Farokhzad, Omid C. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 :2-25
[7]  
Burkhart DJ, 2004, MOL CANCER THER, V3, P1593
[8]  
Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/NNANO.2011.166, 10.1038/nnano.2011.166]
[9]   The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect [J].
Fang, Jun ;
Nakamura, Hideaki ;
Maeda, Hiroshi .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (03) :136-151
[10]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171